Take­da goes all in with build-to-buy play, pick­ing up Mav­er­ick and its clin­ic-ready T cell en­gagers for $525M

As soon as Take­da and Mav­er­ick tied the bow on a $125 mil­lion pact in 2017, a count­down was set off: The phar­ma gi­ant — then in the process of over­haul­ing its R&D op­er­a­tions and as­sem­bling an im­muno-on­col­o­gy pipeline — had five years to watch and lend a hand in its lit­tle biotech part­ner’s pre­clin­i­cal work on T cell en­gagers and de­cide whether to snap it up or not.

It didn’t end up tak­ing that long.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER